基本信息
浏览量:53
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Dr. Hamutal Meiri has a BSc (1973) in Biology from BenGurion University, a PhD in Neurobiology (1979) from the Hebrew University, and a MBA (1995) from Tel Aviv University. She served as a faculty member in molecular brain development in the medical schools of Tel Aviv University (1982-1984), Technion (1984-1989), and NYU (1989-1990). Then she was the first Director of Israel National Committee of Biotech (1991-1994), and served as an advisor to COBIOTECH - the UNESCO committee to promote the development of research, industry and training in Biotech via international cooperation (1992-1995). Subsequently she served as the Director of Algae Biotech Consortium of Israel Chief Scientist Magnet program (1995-1999), and as the Head of Israel Telemedicine Industry Forum (1996-1998). She was appointed also as the Director of North Carolina-Israel Science and Technology Fund (1997-2000). In 2001 she became the CEO of DTL, an Israeli biotech start-up company that developed predicting and prevention tools of preeclampsia, a pregancy major disorder. In 2011 the company was acquired by hylabs, Rehovot and she was appointed as a Director of R&D Development projects in Hylabs. Between 2006-2010 she served as the Coordinator of EC Health Project Pregenesys (FP6) and from hylabs she initiated EC Health Project ASPRE (FP7) where she is the Exploitation Director (2013-2016). She is also serving as EC Horizon Projects evaluators in biomarker development and diagnosis. Dr. Meiri is also the CEO and Chairman of TeleMarpe founded in 1996, which is involved in Risk Management in NanoAthero (EC FP7) and directing several initiative in antinatal care, development of biomarkers and new drug therapy. In 2014 she was awarded the Zatam fund for advanced technology infrastructure as research coordinator of Hylaboratories Ltd, Rehovot Israel. In 2015 she obtained the BIRD grant for the Obediome project wfor the cooperative efforts of hy laboratories with GENEWIZ USA.
In 2013 she became the exploitation manager of the ASPRE project for screening the risk to develop preeclampsia and its prevention by Aspirin. She is currently involve din developing biomarkers for preeclampsia and its prevention by placental protein 13. She is also a member of the PRETWINSCREEN fr identifying algorithms to predict pregnancy complication.
Outside fetal medicine she serves as a consultant for the BIRD foundation and to multiple companies in artificial intelligence, telecommunication and green technologies
研究兴趣
论文共 128 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
American journal of obstetrics & gynecology MFMno. 5S (2024): 101313-101313
Ran Svirsky, Moran Landau Rabbi,Ramzia Abu Hamad,Adi Sharabi-Nov,Nadav Kugler, Narina Galoyan, Nataly Zilberman Sharon,Hamutal Meiri,Ron Maymon,Osnat Levtzion-Korach
Scientific reportsno. 1 (2024): 10813-10813
Journal of Reproductive Immunology (2023): 103675-103675
JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2023)
Ran Svirsky, Moran Landau Rabbi,Ramzia Abu Hamad,Adi Sharabi-Nov,Nadav Kugler, Narina Galoyan, Nataly Zilberman Sharon,Hamutal Meiri,Ron Maymon, Osnat Korach-Lev Zion
Research Square (Research Square) (2023)
Journal of Reproductive Immunology (2023): 104029-16
BMC pregnancy and childbirthno. 1 (2023): 1-6
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn